As­traZeneca of­fers some mixed PhI­II re­sults for se­vere asth­ma, while Roche ri­val floun­ders

As­traZeneca post­ed some mixed — though gen­er­al­ly pos­i­tive — da­ta from two big Phase III stud­ies of ben­ral­izum­ab, its IL-5 con­tender in the high­ly com­pet­i­tive mar­ket for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER